Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Writing Addiction Case Reports for Peer-Reviewed Publications (1 CME)

    Contains 3 Component(s), Includes Credits

    The presenters, editors of ASAM's Journal of Addiction Medicine, aim to provide encouragement and support for addiction specialists to write and submit case reports and to educate trainees.

    Publishing clinical case reports can help communicate new observations and improve clinical care. They also represent scholarship that is do-able for a wide range of addiction clinicians, educators and researchers. Writing a case report is not the same as a clinical research paper nor is it the same as documenting a history and physical. International standards have been developed along with simple checklists to apply them. Journal editors look for the presence of key features in these reports to decide whether they are publishable. In this workshop we will use examples (published, and brought by participants) to discuss international standards by which case reports are evaluated. We will provide guidance regarding how to make it more likely that your case report can be published. The presenters, editors of ASAM's Journal of Addiction Medicine, aim to provide encouragement and support for addiction specialists to write and submit case reports and to educate trainees regarding doing so. As a panel we will entertain questions and answers from the audience. Teaching will be by presentation of standards, group discussion of their application, and review of examples. Attendees are encouraged to send their work in advance or bring it to the workshop. Some will be selected for discussion and critical appraisal. In lieu of those, we will share examples from the literature. During the session we will review case report checklists, apply them to papers, practice developing an outline of content and structure for a case report, and discuss features that make such reports valuable.

    Richard Saitz

    MD, MPH, DFASAM, FACP

    Richard Saitz MD, MPH, FACP, DFASAM is a general internist (DABIM) and primary care physician, an addiction medicine specialist (DABAM), Chair and Professor of Community Health Sciences at Boston University (BU) School of Public Health, and Professor of Medicine at BU School of Medicine. He Chaired the Treatment and Services review committee for the National Institute on Alcohol Abuse and Alcoholism, is Associate Editor of JAMA and Senior Editor of Journal of Addiction Medicine, Section Editor and sole author of key chapters in UpToDate on unhealthy substance use, an editor of the ASAM Principles of Addiction Medicine, and author of >200 peer-reviewed publications http://profiles.bu.edu/display/151440 http://www.bu.edu/sph/profile/richard-saitz/ He was Director of Boston Medical Center’s Clinical Addiction Research and Education (CARE) Unit for over a decade, has been Chairman of an Institutional Review Board, Associate Director of Clinical Research for BU, President of the Association for Medical Education and Research in Substance Abuse (AMERSA), steering committee member of the Motivational Interviewing Network of Trainers (MINT), and was coordinating committee member of International Network for Brief Intervention for Alcohol and other drug problems (INEBRIA). He is Vice President of the International Society of Addiction Journal Editors (ISAJE). His primary areas of expertise supported by NIH, RWJF, and SAMHSA, are screening and brief intervention, integrating substance-related and general health care, improving the quality of care for people with unhealthy substance use, particularly in general health settings, and basing care on science. He validated single-item screening questions recommended by NIDA and NIAAA. Awards: Alpha Omega Alpha Honor Society, Boston Jaycees Ten Outstanding Young Leaders Award, Best Doctors in America®, AMERSA’s W. Anderson Spickard, Jr. Excellence in Mentorship Award, the R. Brinkley Smithers Distinguished Scientist Award (ASAM), Research Society on Alcoholism Distinguished Researcher Award.

    Michael A. Arends

    BSc

    Michael A. Arends, B.Sc., is Senior Research Assistant in the Department of Neuroscience at The Scripps Research Institute, La Jolla, California, where he has worked for the past 20+ years. He graduated in 1995 from the University of California, San Diego, with a bachelor's degree in Psychology. He is currently Managing Editor of Journal of Addiction Medicine (since 2008) and Managing Editor of Pharmacology Biochemistry & Behavior (since 2007). His research interests primarily include drug and alcohol addiction, neuroscience, and neuropsychopharmacology. In 2014, he co-authored the book "Drugs, Addiction and the Brain" with Dr. George Koob and Dr. Michel Le Moal.

    Howard Moss

    MD

    Howard B. Moss, M.D. is Clinical Professor of Psychiatry and Neurosciences at the University of California at Riverside, and Co-Editor of the Journal of Addiction Medicine. He is a board-certified psychiatrist with added qualifications in the subspecialty of Addiction Psychiatry, and is the former Associate Director for Clinical and Translational Research at the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health in Bethesda, Maryland. He has authored over 165 peer-reviewed scientific journal publications and three books. He has been Professor of Psychiatry at University of Pennsylvania, Temple University, and the University of Pittsburgh prior to assuming his role at N.I.H., and has held a Senior Scientist Award from National Institute on Drug Abuse.  His research has focused on the clinical manifestations of substance use disorders, their etiology, and the intergenerational transmission of risk and resilience.  This work has employed diverse methodologies that include psychiatric epidemiology, advanced statistical methods, neurochemistry/neuropharmacology, psychophysiology, biomarker development, neuroimaging, and molecular and behavioral genetics.  Dr. Moss also maintains a private practice of addiction psychiatry in La Jolla, California where he specialized in treating adolescent and adults with problematic involvement with alcohol and drugs, with a special emphasis on abuse of alcohol and prescription opiates. 

    Frank J. Vocci

    PhD

    Frank Vocci, PhD, President and Senior Research Scientist, Friends Research Institute, Baltimore, MD. Following a post-doctoral fellowship in addiction pharmacology at the Medical College of Virginia, Dr. Frank Vocci spent 11 years at the FDA, rising to the level of Chief of the Drug Abuse Staff. At the FDA, he reviewed applications for marketing of medications for analgesic medications and for the treatment of substance abuse disorders. He also participated in domestic and international drug control issues. In 1989, he joined the Medications Development Program at the National Institute on Drug Abuse. He became the Director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMC) in 1997 where he was responsible for overseeing research and development activities in medications development for the treatment of addictive disorders. He was also responsible for biomedical research in the medical consequences of drug abuse, primarily AIDS and hepatitis C research. During his tenure, the DPMC collaborated on the development of four addiction drug products that were approved by the FDA. Dr. Vocci has published over 100 articles in neuropharmacology and the treatment of substance abuse and its consequences. In 2001, he received a Meritorious Executive award from President Bush for his management of the NIDA medications development program. Dr. Vocci also received a Distinguished Service Award in 2003 from the College on Problems of Drug Dependence for his contributions to the development of buprenorphine as a treatment for opiate dependence. In 2006 Dr. Vocci received the Vernelle Fox award from the California Society of Addiction Medicine and the FeDerSerD (Italian Addiction Society) award. Dr. Vocci has been a co-editor of the Journal of Addiction Medicine since 2012 and is a past-president of the College on Problems of Drug Dependence.

    Martha J. Wunsch

    MD, FAAP, DFASAM

    Martha J Wunsch, MD, FAAP , DFASAM is an addiction specialist with The Permanente Medical Group in Northern California. She is the Program Director for the Kaiser Addiction Medicine Fellowship and Medical Director of the San Leandro Hospital Addiction Medicine Consultation and Liaiason Service. Marty earned a medical degree at Uniformed Services University of the Health Sciences in Bethesda, Maryland, completed a pediatric internship and residency at Children’s Hospital Los Angeles (1983-1986), and practiced general pediatrics in the Indian Health Service in Arizona.

    Dr. Wunsch was the Hoff Addiction Medicine Fellow at Medical College of Virginia/Virginia Commonwealth University (2000-2002). She is a distinguished fellow of the American Society of Addiction Medicine and a founding co-editor of the Journal of Addiction Medicine. Dr. Wunsch is a founding director of the American Board of Addiction and the President Elect of The Addiction Medicine Foundation.

  • Opening Scientific Plenary & Distinguished Scientist Lecture (2 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    The opening session will focus on the dawn of a new day in addiction medicine with an exciting lineup of ASAM award winners and luminaries in the field.

    Joseph Green A Beacon of Hope: There Are No Lost Causes As a spoken word artist, motivational speaker, and activist for the recovery community, Joseph Green uses poetry interwoven with storytelling to share his battle with addiction and subsequent recovery to deliver a message of inspiration to people who have chosen careers in prevention, intervention, and treatment. Using his own story, Joseph reconnects his audience to the source of their motivation, reminding them that, as important as it is to know what we are fighting against, it is more important to remember what we are fighting for Patrice Harris, MD, MA Sparking Change: The Providers' Role in Combatting the Opioid Crisis Prescription opioid misuse, overdose and death continues to be one of our nation's most complex and challenging public health threats. The American Medical Association and its partner organizations on the Task Force to Reduce Opioid Abuse are working to reverse the epidemic through physician leadership. These efforts include urging physicians to use Prescription Drug Monitoring Programs, enhancing physician education, increasing access to treatment for substance use disorders, promoting comprehensive pain care, including non-opioid and non-pharmacologic care, expanding access to the life-saving drug naloxone, and strengthening state Good Samaritan protections for bystanders who intervene to help overdose patients. As chair of the Task Force, and Board Chair at the AMA, Dr. Patrice Harris will examine key data and policy trends at state and national levels, discuss their effectiveness, and highlight specific efforts still needed to reverse the nation's opioid epidemic. Barbara Mason, PhD Shedding New Light on an Old Problem: Novel Treatments for Alcohol Use Disorder Recent advances in our understanding of the neurobiology of alcohol use disorder can serve as the basis for the development of novel pharmacotherapies. Specifically, the activation of brain stress systems in early abstinence offers pharmacological targets that can be restored to a homeostatic range of functioning and thereby support recovery. Results from clinical trials of novel medications in this domain will be presented, with implications for clinical practice. Vice Admiral Vivek H. Murthy, MD, MBA Facing Addiction: Shining a Spotlight on America's Most Pressing Public Health Issue In his 2016 breakthrough report, US Surgeon General Murthy showed the nation the ubiquitous reach of substance use and addiction in this country. Using staggering data, he defined the public health impact of substance misuse, but also illustrated the tremendous impact that resonates throughout every community. Vice Admiral Vivek H. Murthy will discuss what led to the release of this landmark publication, what the country's next steps will be, and why there is still reason to hope.

    Joseph Green

    Joseph Green is a spoken word artist, educator, and motivational speaker.  Over the past 10 years Joseph’s passion for youth development has led to him supporting young people in a multitude of facets.  He the co-founder and former Program Manager of poetryN.O.W., an after school creative writing program that worked with students throughout the DC metropolitan area.  After five years of successful programming, poetryN.O.W. was acquired by Split This Rock, a Washington DC based poetry and social justice organization, where Joseph now supervises youth programs in over 25 high schools.  In his work with poetryN.O.W. and Split This Rock, Joseph has also crafted an extensive creative writing curriculum now used in classrooms throughout the country.

    In his prevention work with high schooled aged youth, Joseph facilitates interactive workshops to create transformational original poems on the effects that substance abuse and addiction has had on their lives. By empowering students to speak truth to power, Joseph has provided opportunities for them to share their stories with policy makers at the White House for the US Office of National Drug Control Policy and the US Department of Education. In his role as Program Manager at the Mentor Foundation USA, Joseph led the effort to revamp the interactive drug prevention youth rally known as Shattering the Myths.  As part of this initiative, he also served as host for the three day program that included a full day of writing workshops and leadership training.
    2015 marked Joseph’s fifth return to Poetry Slam International’s national slam, this time as a representative of the DC Poetry Slam Team. He represented the Oneonta slam team in 2005 and 2006 as their Grand Slam Champion, Slam Richmond in 2009, and DC’s Beltway Poetry Slam team in 2011. He also represented DC in 2011 at the Individual Poetry Slam, ranking 16th in the world. As a solo artist, Joseph has performed, hosted, and featured at venues and schools throughout the United States, including the White House and Kennedy Center. He has over ten years experience as a professional spoken word artist and writer.
    Joseph believes in the power of using lived experiences to catalyze positive personal change, and often pulls from his own unique set of experiences to engage groups of all ages and backgrounds. In 2012 he started the interactive performance series, Dive Every Day Project, with the intent of opening dialogue around the topic of substance use disorder, addiction, and recovery. The Dive Every Day Project pulls from a catalog of original work dealing directly with these issues, drawing from personal and family experiences. Dive Every Day serves to be a tool of inspiration and guidance for all who encounter it and is a testament to self-forgiveness, redemption, and the irreplaceable role of love in the human revolution.

    Patrice A. Harris

    MD, MA

    Dr. Patrice Harris, a psychiatrist from Atlanta, is chair of the American Medical Association’s (AMA) Board of Trustees.

    Active in organized medicine her entire career, Dr. Harris has held many leadership positions at both the national and state level.  In addition to serving on the AMA’s Board of Trustees since 2011, Dr. Harris previously served as chair of the AMA’s Council on Legislation, and on the boards of the American Psychiatric Association and the Georgia Psychiatric Physicians Association.
    As past director of Health Services for Fulton County, Georgia, which includes Atlanta, Dr. Harris oversaw all county health-related programs and functions, and spearheaded the county’s efforts to integrate public health, behavioral health and primary care services.
    Governing themes in Dr. Harris’ professional life are a passion to improve the lives of children and service to others, and she has worked for children both clinically and in the advocacy arena.
    A key focus for Dr. Harris currently is developing solutions to end the nation’s opioid epidemic.  She is chair of the AMA’s Task Force to Reduce Opioid Abuse, which brings together specialty and state medical societies and other health care associations to move swiftly to implement best practices to combat the opioid epidemic and save lives.

    Barbara Mason

    PhD

    Barbara J. Mason, Ph.D. is the Pearson Family Professor, Director of the Pearson Center for Alcoholism and Addiction Research, Director of the Laboratory of Clinical Psychopharmacology, and Acting Chair of the Committee on the Neurobiology of Addictive Disorders at The Scripps Research Institute, La Jolla, CA. Dr. Mason's work in medication development for the treatment of alcohol use disorders has been recognized with a MERIT Award from the National Institutes of Health (NIH), the Dean's Senior Clinical Research Award from the University of Miami School of Medicine, and the Andrew W. Mellon Foundation Teacher-Scientist Award from Cornell University Medical College. Dr. Mason conducted the seminal studies identifying nalmefene as having therapeutic potential for alcohol dependence; nalmefene (Selincro) has recently received regulatory approval for the treatment of alcohol dependence in the European Union. Dr. Mason also served as overall Principal Investigator for the US multicenter trial of acamprosate (Campral) for the treatment of alcohol dependence which was conducted in support of FDA approval. Dr. Mason has served on the National Advisory Councils of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Advisory Council of the National Institute on Drug Abuse (NIDA). Dr. Mason is an elected Fellow of the American College of Neuropsychopharmacology and has held multiple editorial positions, including serving as a current member of the editorial board for the Journal of Addiction Medicine. Dr. Mason holds the Pearson Family Chair, an endowed position in alcohol and addiction research at The Scripps Research Institute, and is currently conducting a program of NIH-funded research that includes human laboratory studies to screen medications for therapeutic potential for alcohol dependence and clinical trials to evaluate the safety and efficacy of novel medications for alcohol and cannabis dependence.

    Vivek H. Murthy

    Vice Admiral, MD, MBA

    Vice Admiral (VADM) Vivek H. Murthy, M.D., M.B.A., was nominated by President Barack Obama in November 2013 and confirmed on December 15, 2014 as the 19th United States Surgeon General. As America’s Doctor, Dr. Murthy is responsible for communicating the best available scientific information to the public regarding ways to improve personal health and the health of the nation. He also oversees the operations of the U.S. Public Health Service (USPHS) Commissioned Corps, comprised of approximately 6,700 uniformed health officers who serve in locations around the world to promote, protect, and advance the health and safety of our nation. 

    Dr. Murthy has devoted himself to improving public health through the lens of service, clinical care, research, education, and entrepreneurship. The son of immigrants from India, Dr. Murthy discovered a love for the art of healing early in his childhood while spending time in his father’s medical clinic in Miami, Florida. After attending Miami Palmetto Senior High School, he received his Bachelor’s degree from Harvard, and his M.D. and M.B.A. degrees from Yale. He completed his residency training at Brigham and Women’s Hospital and Harvard Medical School where he later joined the faculty as an internal medicine physician and instructor. As a clinician-educator, Dr. Murthy has cared for thousands of patients and trained hundreds of residents and medical students. He regards caring for patients as the greatest privilege of his life.  
    In addition to clinical practice, Dr. Murthy has two decades of experience and perspective improving health in communities across the country and around the world. He co-founded VISIONS, an HIV/AIDS education program in India and the United States, which he led for eight years. As its president, he established ten chapters with hundreds of volunteers in both countries and grew the organization’s education programs to reach more than 45,000 youth. Dr. Murthy also co-founded the Swasthya project (“health and wellbeing” in Sanskrit), a community health partnership in rural India, to train women to be health providers and educators. During his five-year tenure with the organization, he established seed funding and helped expand research and direct care programs that reached tens of thousands of rural residents.
    As a research scientist, Dr. Murthy has conducted laboratory research on vaccine development and studied the participation of women and minorities in clinical trials. His research findings have been published in Science, the Journal of the American Medical Association, and the Journal of the National Cancer Institute. Dr. Murthy is also a healthcare entrepreneur and innovator. He co-founded and chaired a successful software technology company, TrialNetworks, which improves research collaboration and enhances the efficiency of clinical trials around the world. In seven years, Dr. Murthy and his team took the company from conception to an international enterprise that powers dozens of clinical trials for over 50,000 patients in more than 75 countries. Dr. Murthy has also served as the president of Doctors for America, a non-profit organization with more than 16,000 physicians and medical students in all 50 states who work with patients and policymakers to build a high quality, affordable health system for all.
    Seen by many as a proven leader who can use 21st century approaches and technology to modernize the role of Surgeon General, Dr. Murthy will focus his efforts on building cross-sector partnerships in communities to address the epidemics of obesity and tobacco-related disease, to reduce the stigma associated with mental illness, to improve vaccination rates, and to make prevention and health promotion the backbone of our communities. Dr. Murthy firmly believes that our nation's greatest strength has always come from its people. Improving the health of our people means strengthening our communities and our country. That will be Dr. Murthy’s highest priority as Surgeon General. 

  • Addiction 60/60: All of Addiction Medicine in 60 Slides and 60 Minutes (1.5 CME)

    Contains 3 Component(s), Includes Credits

    This session offers an ultra-fast-paced, “state-of-the-art” review of 2017 Addiction Medicine in the context of our current understanding of the addictive process. We will review how current neurobiology approaches craving and control, and how these novel concepts inform our treatment options, both pharmacological and psychosocial.

    Addiction specialists these days do much more than treat patients. Educating people about addiction and helping them understand the disease from a medical perspective is a ubiquitous request. From giving a Grand Rounds presentation to seasoned attending physicians to training hospital staff through in-service programs to responding to the media, we are often called on to talk about addiction and its treatments. In this workshop, we will attempt to refine a one-hour PowerPoint lecture that covers the essentials of Addiction Medicine in 2017. We will strictly use 60 slides with no more than 60 words per slide to deliver the lecture. The first part, the Fundamentals of Addiction Medicine will cover (1) the Neurobiology of Addiction; (2) Alcohol; (3) Sedatives; (4) Opioids; (5) Stimulants; (6) Nicotine; (7) Cannabis; (8) Dissociatives, Hallucinogens, and Steroids; and (9) the Behavioral Addictions. The second part, Assessments and Treatments will address (1) the Epidemiology of Addiction; (2) Public Policy; (3) Screening, Brief Intervention, and Referral to Treatment (SBIRT), ASAM Patient Placement Criteria (PPC), and other Assessment Tools; (4) Toxicology Examinations; (5) 12-Step Programs; (6) Cognitive Behavior Therapy; (7) Motivational Interviewing; (8) Medical Co-Morbidities; and (9) Psychiatric Co-Morbidities. Finally, the third part, Special Populations and Topics will look into (1) Pain and Addiction; (2) Maternal/Child Issues; (3) Adolescents; (4) the Elderly; (5) Impaired Professionals; and (6) the Future of Addiction Medicine. This 24-part review of our field can also serve as a basic template for the development of full-day or multiple-day courses in Addiction Medicine. During the second hour of the workshop, the presenters will invite participants to critique the presentation; change, add, or delete topics and slides; and discuss the usefulness of such an admittedly ambitious undertaking. This is the second time that we will try this approach-- the first time we attempted the 60/60 was at the 2013 ASAM Med-Sci Conference in Chicago. We have refined the presentation since then, based on feedback we have received from students, trainees, and fellow addiction specialists.

    Petros Levounis

    MD, MA, DFASAM

    Dr. Levounis is a Phi Beta Kappa graduate of Stanford University where he studied chemistry and biophysics before receiving his medical education at Stanford University School of Medicine and the Medical College of Pennsylvania. During medical school, he received an MA degree in sociology from Stanford before moving to New York City where he trained in psychiatry at Columbia University. He graduated from Columbia receiving the National Institute of Mental Health Outstanding Resident Award and went on to complete his fellowship in addiction psychiatry at New York University. From 2002 to 2013, he served as director of the Addiction Institute of New York.
    Dr. Levounis has written numerous articles and monographs; has lectured extensively on addiction topics throughout the United States and abroad; and has been interviewed by all major television networks. Dr. Levounis serves on the Board of Directors of the American Society of Addiction Medicine (ASAM) and from 2005 to 2009 chaired the national Committee on Addiction Treatment of the American Psychiatric Association. Dr. Levounis is a Betty Ford Scholar, a recipient of a U.S. State Department Speaker and Specialist Award, a distinguished fellow of the APA and ASAM, and an honorary member of the World Psychiatric Association. 

    Dr. Levounis has published thirteen books including the self-help paperback “Sober Siblings: How to Help Your Alcoholic Brother or Sister—and Not Lose Yourself,” the textbook of “Substance Dependence and Co-Occurring Psychiatric Disorders,” “The Behavioral Addictions,” “Motivational Interviewing for Clinical Practice,” “Becoming Mindful,” and the “Office-Based Buprenorphine Treatment of Opioid Use Disorder,” now in its second edition. His books have been translated into German, Hungarian, Japanese, Portuguese, and Spanish. 

    Dr. Levounis is married to actor Lukas Hassel and lives in New York City.

  • National Perspectives Plenary (1 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This lively session will give attendees the opportunity to interact with representatives from SAMHSA, NIAAA, and NIDA.

    The National Perspectives Plenary Session is new this year and was created to provide the opportunity for leaders of federal agencies to address emerging issues and advances in addiction medicine with short, pointed presentations. Attendees will have the opportunity to ask questions of agency leaders during the last half of the session. Moderated by ASAM President, R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM and Annual Conference Program Planning Committee Chair, Michael Fingerhood MD, FACP, this lively session will give attendees the opportunity to interact with representatives from SAMHSA, NIAAA, and NIDA.

    Kana Enomoto

    MA

    Ms. Enomoto has been delegated—by the Department of Health and Human Services Secretary Sylvia M Burwell—the functions, duties, and authorities of the Administrator to oversee an agency with four centers, four offices, over 600 employees, and a budget of $3.7 billion. Through data, policy, public education, and grants, Ms. Enomoto and the SAMHSA team advance the agency's mission to reduce the impact of substance abuse and mental illness on America's communities. Ms. Enomoto has served as Principal Deputy Administrator and principal advisor to the SAMHSA Administrator on operations, policies, and programmatic activities for the agency since August 2011. Prior to that, Ms. Enomoto served as the Director of the Office of Policy, Planning, and Innovation, where she developed, coordinated, and communicated SAMHSA policies across the full spectrum of mental health and substance abuse issues. From 2005-2009, Ms. Enomoto served as the Principal Senior Advisor to three SAMHSA Administrators, and as the Acting Deputy Administrator between 2008 and 2009. She began her tenure at SAMHSA in 1998 as a Presidential Management Fellow. She began her career in research and clinical services with a focus on minority mental health and trauma. Ms. Enomoto has received awards in recognition of her work, including the Arthur S. Flemming Award, the American College of Mental Health Administration King Davis Award, and the Secretary's Award for Distinguished Service. Ms. Enomoto earned her bachelor's degree in psychology and master's degree in clinical psychology from the University of California, Los Angeles and is a graduate of Harvard University's Kennedy School of Government, Senior Managers in Government Program.

    George F. Koob

    PhD

    George F. Koob, PhD is Director of the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health, Washington, DC. As an authority on alcoholism, drug addiction and stress, he has contributed to our understanding of the neurocircuitry associated with the acute reinforcing effects of alcohol and drugs of abuse and the neuroadaptations of the reward and stress circuits associated with the transition to dependence. Dr. Koob has published over 650 peer reviewed papers and several books including the “Neurobiology of Addiction," a comprehensive treatise on emerging research in the field. He has mentored 11 PhD students and over 75 post-doctoral fellows.

    Wilson Compton

    MD, MPE

    Dr. Wilson M. Compton serves as the Deputy Director of the National Institute on Drug Abuse (NIDA) of the National Institutes of Health. In his current role, Dr. Compton's responsibilities include providing scientific leadership in the development, implementation, and management of NIDA's research portfolio and working with the Director to support and conduct research to improve the prevention and treatment of drug abuse and addiction. Prior to his current appointment, Dr. Compton served as the Director of NIDA's Division of Epidemiology, Services and Prevention Research from 2002 until 2013. In this leadership role, he oversaw the scientific direction of a complex public health research program of national and international scope addressing: 1) the extent and spread of drug abuse, 2) how to prevention drug abuse, and 3) how to implement drug abuse prevention and treatment services as effectively as possible. Before joining NIDA, Dr. Compton was Associate Professor of Psychiatry and Director of the Master in Psychiatric Epidemiology Program at Washington University in Saint Louis as well as Medical Director of Addiction Services at the Barnes-Jewish Hospital in Saint Louis. Dr. Compton received his undergraduate education from Amherst College. He attended medical school and completed his residency training in psychiatry at Washington University. During his career, Dr. Compton has achieved multiple scientific accomplishments: he was selected to serve as a member of the DSM-5 Revision Task Force; is the author of more than 130 articles and chapters; and is an invited speaker at multiple high-impact venues. Dr. Compton is the recipient of multiple awards and in 2008, he received the Senior Scholar Health Services Research Award from the American Psychiatric Association, in 2010 the Paul Hoch Award from the American Psychopathological Association, in both 2012 and 2013, he was selected to receive the Leveraging Collaboration Award from the Food and Drug Administration. In 2013, Dr. Compton received the prestigious Health and Human Services Secretary's Award for Meritorious Service.

  • Fetal Alcohol Spectrum Disorders: Prevention, Diagnosis and Management in Primary Care (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This interactive, multimedia focus session will provide the primary care clinician a primer on addressing unhealthy alcohol exposure across the lifespan with a focus on FASDs diagnosis, management and prevention. We will discuss how to screen for, diagnosis, manage and refer patients with FASDs in the primary care setting. We will also review two evidence-based approaches to alcohol exposed pregnancy prevention in primary and integrated care systems, alcohol Screening and Brief Intervention (aSBI) and the CHOICES interventions. Lastly we will share strategies to promote a safe and supportive, stigma-free practice environment for patients with FASDs and their families.

    This focus session will provide the primary care clinician a primer on addressing unhealthy alcohol exposure across the lifespan with a focus on FASDs diagnosis, management and prevention. Fetal Alcohol Spectrum Disorders (FASDs) are the number one cause of preventable birth defects and the leading cause of developmental disabilities in the United States. Primary care clinicians are in a unique position to diagnose, manage and prevent FASDs. While the prevalence of FASDs rivals that of autism spectrum disorders, they are not routinely screened for in well child visits, and not often considered in the diagnostic differential of adult patients with complex psychosocial histories and adherence issues. Too often the diagnosis is missed. And yet early diagnosis and management are key to improved prognosis. Primary care clinicians can make a difference through increased awareness of FASDs' diagnostic criteria and clinical presentations, enhancing efforts toward early recognition within their patient populations. FASDs are irreversible disorders requiring lifelong interdisciplinary care and support to maximize function and minimize disability. Primary care clinicians and patient centered medical homes, as experts in the management of complex, chronic medical conditions, are well-positioned to provide the care coordination and management required for patients with FASDs. Primary care clinicians and practices can also play a key role in FASD prevention. Unhealthy alcohol use is common in primary care patients, and addressing unhealthy alcohol use in primary care through screening and brief intervention (SBI) is a US Preventive Services Task Force grade B recommendation. Providing SBI to all adolescent and adult patients in a primary care practice is one way of reducing alcohol exposed pregnancies. We will also review another set of evidence based approaches that have also been successfully implemented in integrated primary care practices, the CHOICES interventions. Effective diagnosis, management and prevention of FASDs hinge on addressing the stigma associated with FASDs and alcohol exposed pregnancies (AEPs). We will discuss how to promote a safe and supportive, stigma-free practice environment for patients with FASDs and their families.

    Alicia A. Kowalchuk

    DO, FASAM

    Alicia Kowalchuk, DO is an assistant professor with Baylor College of Medicine’s (BCM) Department of Family and Community Medicine and board certified in both family medicine and addiction medicine. She is medical director of InSight, the SBIRT program for the Harris Health System, treating patients at the InSight Clinic, an interdisciplinary clinic providing ambulatory addiction medicine and counseling services to Harris Health patients with substance use disorders (SUD).

    She also serves as medical director at Santa Maria Hostel (SMH) which provides state-funded residential SUD treatment services to women in the greater Houston community and the Houston Recovery Center which operates a Sobering Center in partnership with the City of Houston and Houston Police Department. She is part of two SAMHSA funded initiatives, which expand and integrate on site behavioral health services and medication assisted treatment for women clients and their extended families at SMH.   
    Her current research includes a NIAAA funded randomized controlled trial of a pre conception counseling intervention for reducing tobacco, alcohol and marijuana exposed pregnancy risk, the CHOICES4Health study.   As core faculty of the CDC funded BCM Fetal Alcohol Spectrum Disorder Practice and Implementation Center (FASD PIC), her focus is on alcohol exposed pregnancy prevention implementation in primary care practices.  
    Dr. Kowalchuk graduated from New York College of Osteopathic Medicine, performing her internship at St. Clare’s Hospital in Manhattan.  She completed her family medicine residency at Montefiore Medical Center in the Bronx and then served three years with the National Health Corps providing on site prenatal, HIV, primary care and addiction medicine services at a methadone clinic in the South Bronx.  She joined the BCM faculty in 2004.  Her passion is caring for families affected by addiction and educating other healthcare professionals and students about effectively and compassionately delivering that care. 

    Mohamad A. Sidani

    MD

    Mohamad A. Sidfani, MD, MS. is professor and Vice Chair for Clinical Affairs in  the Family and Communuity Medicine Department at baylor College of Medicine Houston, TX. He served in similar capacity at Meharry Medical College in Nashville, Tennessee. Dr. Sidani completed his Family medicine Residency at Anderson Memorial Hospital in Anderson, South Carolina and Geriatric fellowship at the University of Michigan in Ann Arbor. He also received a Masters in Clinical Research Design and Biostatistics from the University of Michigan. Dr. Sidani is board certified in Family Medicine and has CAQ in Geriatric Medicine. Dr. Sidani has more than 15 years of academic and administrative experience. He is well-published in peer-reviewed journals such as American Family Physician and Clinics in Geriatric Medicine. He has been honored with several awards including the AAFP Foundation Pfizer Immunization Award, and outstanding teacher award for his work at Meharry Medical College and at Louisiana State University Health Sciences Center at New Orleans, Louisiana.

    Sandra J. Gonzalez

    MSSW, LCSW

    Sandra J. Gonzalez, MSSW, LCSW is an Instructor and Licensed Clinical Social Worker at Baylor College of Medicine in Houston, Texas. She is Research faculty and a practicing behavioral health clinician. She is Co-Investigator on the CDC-funded Fetal Alcohol Spectrum Disorders (FASD) Practice and Implementation Centers project as well as the SAMHSA-funded SBIRT Health Professions Student Training grant currently being carried out at the University of Texas, Rio Grande Valley. She has previously implemented alcohol screening and brief intervention in primary care practices in Tennessee and Texas, developing and delivering educational materials on FASD prevention to medical and allied health providers and students. Her clinical and research interests include evidence-based behavioral health interventions, with an emphasis on preventive services and trauma-informed care, prevention of alcohol-exposed pregnancy (AEP), and reducing health inequities. 

  • Effective International Collaboration in the Addiction Field (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    The membership of the International Society of Addiction Medicine (ISAM), established in 1998, includes a large, worldwide representation of addiction specialists who have regularly met to present and exchange their respective findings. Speakers at this session will present findings from research and their clinically applicable experiences that can shed light on the problems we confront here in the United States.

    Abstract: International clinical research on substance use disorders has seen remarkable growth in recent years. While some of this growth can be attributed to new modalities of treatment for the very same problems and disorders confronting American clinicians in the addiction field, other clinical studies address problems different from our own, yet still ones that shed light on the issues confronted in the American treatment community. The membership of the International Society of Addiction Medicine (ISAM), established in 1998, includes a large, worldwide representation of addiction specialists who have regularly met to present and exchange their respective findings. Speakers at this session will present findings from research and their clinically applicable experiences that can shed light on the problems we confront here in the United States. These presentations illustrate how we can broaden and extend our competency in addiction treatment and research by leveraging the unique experience drawn from the international arena. Participants will explore innovative aspects of clinical addiction medicine from an international perspective and learn about the role of NIDA and ISAM in addiction care and research. As a result, they will become better able to provide and organize care for addicted patients. Dr. Jeffrey Wilkins (UCLA) will speak on addiction treatment in the Middle East, Dr. Marc Galanter (NYU) will speak on Narcotics Anonymous in Iran; Dr. Shruti H. Mehta (Johns Hopkins) will speak on HIV/HCV and drug abuse in India, and finally Dr. Tarek el-Gawad (University of Cairo) will discuss the development of addiction services in the UAE.

    Gregory C. Bunt

    MD, FASAM

    Dr. Gregory Bunt graduated from NYU School of Medicine in 1983, completed his residency in Psychiatry at the AECOM in 1987, and a Fellowship in Addiction Psychiatry at NYU (1989), and is currently as an Assistant Clinical Professor of Psychiatry at NYU. He is a diplomat of the American Board of Psychiatry and Neurology in Addiction Psychiatry. Dr. Bunt is currently the medical director of Daytop Village and consultant to Daytop International. Dr. Bunt also serves as the President of the New York Society of Addiction Medicine and the President-Elect of the International Society of Addiction Medicine as well. He has authored over a dozen publications, and speaks nationally and internationally on the subject of therapeutic communities.

    Jag Khalsa

    PhD, MS

    Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a Ph.D. in neuro-psycho-pharmacology, a Master's degree in herbal pharmacology/medicine, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International. E-mail: jk98p@nih.gov

    Jeffery Wilkins

    MD, DFAPA, DFASAM

    Jeffery N. Wilkins, M.D., DFAPA, DFASAM, is the Lincy/Heyward-Moynihan Endowed Inaugural Chair in Addiction Medicine, Dept. of Psychiatry & Behavioral Neurosciences, Cedars-Sinai Medical Center (CSMC). Dr. Wilkins received his undergraduate degree from University of Notre Dame, his MD from University of California, San Diego, and psychiatric training at UCLA followed by a Career Development award from the Veterans Administration. Dr. Wilkins also serves on the boards of both the American Society of Addiction Medicine (ASAM) and the American Board of Addiction Medicine (ABAM); and he is also on the board of the Brent Shapiro Foundation for Drug Awareness. He previously served as the President of the California Society of Addiction Medicine, the Board Chair of the Psychological Trauma Center (CSMC) and inaugural Senior Editor of the Journal of Military Behavioral Health (MBH, Taylor & Francis, publishers). During Dr. Wilkins tenure as Senior Editor, the journal presented special issues and spotlights on: protective and risk factors for returning male and female veterans, intimate partner violence, and behavioral health of children in military families. In a special housing project with homeless veterans in Los Angeles, Dr. Wilkins' tracked outcomes of homeless veterans with substance abuse problems in Los Angeles. The results contributed to the Congressional and Senate passage of national funding for providing housing and treatment to homeless veterans across the country. Dr. Wilkins founded, and served as Program Director of the ACGME fellowship in Addiction Psychiatry at CSMC for 14 years, graduating 18 fellows; the training program is now sponsored within the Greater Los Angeles VAHCS - UCLA/San Fernando Valley Psychiatry Training Programs. His investigations have received funding from the National Institute on Drug Abuse, the National Institute of Mental Health and the Veterans Administration. Dr. Wilkins has written 23 chapters and over 60 articles for numerous peer-reviewed publications.

    Marc Galanter

    MD, DFASAM

    Marc Galanter, M.D., is a Professor of Psychiatry at NYU, Founding Director of the Division of Alcoholism and Drug Abuse, a Senior Editor of the Journal “Substance Abuse,” and co-editor of the American Psychiatric Association's “Textbook of Substance Abuse Treatment.” He has written four books, “Cults: Faith, Healing, and Coercion,” “Network Therapy for Alcohol and Drug Abuse,” “Spirituality and the Healthy Mind,” and "What is Alcoholics Anonymous?", and published over 200 peer-reviewed articles. His NIH and foundation-funded studies have addressed network therapy for substance abuse, pharmacologic treatment for addiction, the psychology of Twelve-Step recovery, and spirituality in healthcare.

    Dr. Galanter attended Albert Einstein College of Medicine where he did his residency in psychiatry. After that he was a Clinical Associate of the National Institute of Mental Health, then an NIH Career Teacher. He later served as President of the Association for Medical Education and Research in Substance Abuse (AMERSA, 1976-1977), the American Academy of Addiction Psychiatry (AAAP, 1991-1992), and the American Society of Addiction Medicine (ASAM, 1999-2001). Among his awards are the Gold Achievement Award for Innovation in Clinical Care, the Oskar Pfister Award for Spirituality, Religion and Psychiatry, and the Seymour Vestermark Award for Psychiatric Education, all from the American Psychiatric Association; the McGovern Award for Medical teaching from AMERSA; the Smithers Award for Research form ASAM; and New York State's Award for Psychiatric Research.

    Shruti H. Mehta

    PhD, MPH

    Shruti Mehta is a Professor and the Deputy Chair of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. She received a Master’s in Public Health and a PhD in Epidemiology also from the Johns Hopkins Bloomberg School of Public Health. Her research focuses on HIV and hepatitis C virus (HCV) infection among people who inject drugs (PWID) in the US and in India with a particular interest and focus on identifying and overcoming barriers to access care and treatment for HIV and HCV. 

    Tarek M. Gawad

    MD

    Tarek M. Gawad, MD is the Acting Director, New Psychiatric and Addiction Hospital at Cairo University.

  • Opioid Overdose and Substance Use Disorder Treatment: Prevention and Response Strategies (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This workshop session will provide an opportunity for attendees to learn about SAMHSA’s detailed overdose prevention and response curriculum including its purpose, content, and how to use and adapt it. Presenters will discuss strategies for overdose prevention and SAMHSA’s priorities and prevention efforts for addressing the nation’s heroin/opioid overdose epidemic. The discussion will include details of increasing naloxone access such as considerations related to naloxone product(s), liability discussions for organizations and individuals, and adapted agency protocols. Presenters will also share lessons learned about working with community stakeholders and developing collaborative interagency relationships to address opioid overdose prevention using naloxone.

    This workshop session will provide an opportunity for attendees to learn about SAMHSA's detailed overdose prevention and response curriculum including its purpose, content, and how to use it. This workshop will be moderated by LCDR Brandon Johnson. Dr. Anthony Campbell will discuss SAMHSA's overdose prevention and response priorities and the products, funding, and technical assistance related to the nation's heroin/opioid overdose epidemic. Maya Doe-Simkins will discuss opportunities that SUD treatment providers have to access people at risk for overdose and how the curriculum can be adapted and utilized to implement strategies for reaching this population. Her discussion will focus on models for integrating overdose prevention in SUD treatment programs, strategies for addressing common barriers and maximizing on-site safety. Dr. Sharon Stancliff will facilitate a discussion of some of the nuanced details of increasing naloxone access through SUD treatment organizations or collaboration with other organizations in the community. For example: How to make decisions about which naloxone product(s) to use? Should the overdose response protocol include chest compressions or rescue breathing? What are the liability risks for organizations and individuals? What does an appropriate agency protocol look like? What are good combinations for interagency collaborations? What kind of supervision or oversight does an overdose prevention program require? Chin Hwa (Gina) Dahlem will discuss her work integrating naloxone prescribing and distribution into health care for people experiencing homelessness. She and Dr. Stancliff will also discuss models for overdose prevention collaborations with prisons, jails, law enforcement, and community laypersons. She will provide insights for effective messaging based on context and opportunities and strategies for collaboration with community stakeholders. LCDR Brandon Johnson will facilitate questions and answers and will conclude the workshop with an explanation of activities and opportunities for overdose prevention support that reflect SAMHSA's commitment to overdose prevention.

    Sharon Stancliff

    MD, FAAFP

    Sharon Stancliff, M.D. is the Medical Director of the Harm Reduction Coalition She oversees SKOOP, which provides overdose prevention services both directly in New York City and through education and capacity building nationally and internationally. Dr. Stancliff also consults on drug related problems for the AIDS Institute, New York State Department of Health and for several international organizations. 

    Dr. Stancliff graduated from the School of Medicine at University of California at Davis, did her Family Practice residency at the University of Arizona and completed the AIDS Institute-sponsored Nicolas Rango HIV Clinical Scholars Program at Beth Israel Medical Center in New York City. She is board certified in Family Medicine, a Fellow of the American Academy of Family Practice, and certified by the American Board of Addiction Medicine. She serves as secretary for the New York Society of Addiction Medicine.

    Maya Doe-Simkins

    MPH

    Maya Doe-Simkins has been working to prevent overdose for over a decade. She helped develop one of the first naloxone distribution programs using nasal naloxone and was part of the evaluation team that published the first effectiveness study on bystander naloxone. She’s developed curricula and provided overdose prevention technical assistance to federal and state governments as well as community based organizations. She is supporting overdose prevention implementation in Latin America, co-directs PrescribeToPrevent.org, and manages a web-based national naloxone program locator. Maya currently resides part time in her rural Michigan home town and part time in Chicago. Her graduate studies in public health were completed at Tulane University.

    Chin Hwa (Gina) Dahlem

    PhD, FNP-C, FAANP

    Chin Hwa (Gina) Dahlem PhD, FNP-C, FAANP is a Clinical Assistant Professor at the University of Michigan School of Nursing, board certified family nurse practitioner, and Fellow of the American Association of Nurse Practitioners.   She practices and mentors students at Packard Health - Delonis Shelter Health Clinic where she provides primary care services for people who are experiencing homelessness and predominantly teaches in the graduate family and adult nurse practitioner programs.  She is a co-developer of Rapid Assessment for Adolescent Preventive Services which is used worldwide as a comprehensive risk assessment for adolescents and has led opioid overdose prevention trainings using naloxone for law enforcement officers and community organizations throughout southeast Michigan.

    Anthony Campbell

    RPH, DO, CDR, USPHS

    Dr. Anthony Campbell is currently a board eligible candidate in the field of addiction medicine who currently services as a Clinical Specialty Consultant with the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment in the Division of Pharmacologic Therapies (SAMHSA/CSAT/DPT). He and serves as a Commander in the United States Public Health Service. In his role at SAMHSA, he is responsible for planning, directing and evaluating the development of pharmacotherapy-based treatment standards and guidelines that require specialized DPT medical review. In addition he is an adjunct professor at both Howard University Colleges of Pharmacy and Medicine in Washington DC.

    Dr. Campbell earned two bachelor’s degrees from Howard University; Chemistry (85) and Pharmacy (88). He earned his Doctorate of Osteopathic Medicine from Ohio University (94). Additional training followed including a residency in Internal Medicine, with current board certification.

  • Finding Meaning in Suffering: A Workshop on Managing Patients With Complex Problems (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    Human suffering takes many forms, and occurs throughout the lifespan. Physical, emotional, spiritual, and existential suffering are an integral part of human existence, and addiction medicine physicians encounter it on a daily basis. When we encounter patients with complex problems who do not appear to respond to our best efforts to provide care, it can generate negative feelings within us.

    Human suffering takes many forms, and occurs throughout the lifespan. Physical, emotional, spiritual, and existential suffering are an integral part of human existence, and addiction medicine physicians encounter it on a daily basis. When we encounter patients with complex problems who do not appear to respond to our best efforts to provide care, it can generate negative feelings within us. Our responses can range from distancing ourselves from the patient to over involvement with increased feelings of anger and frustration. Most often if because we do not understand and appreciate the dynamics underlying our response. Finding meaning in experience is a fundamental human desire. Recurrent failure to do so can lead to compassion fatigue, burn out, addiction and unprofessionalism in the work place. This facilitated small group session will use the art of story weaving (narrative and improvisation) to safely and gently explore some of the difficult and painful emotions addiction medicine care providers might experience when caring for those who are suffering. The facilitators demonstrate the spirit of motivational interviewing namely compassion, acceptance, partnership and evocation to engage participants in the process of story weaving. We will also evoke the participant's experience and wisdom to discuss how we can support our patients to find meaning and resolution of suffering in their own distress. The session concludes with the co-creation of ways to be aware of these effects on ourselves and how we can be renewed by finding meaning in our practice.

    Peter Selby

    MBBS, CCFP, FCFP, DFASAM

    Peter Selby MD is the Director of Medical Education and a Clinician Scientist at the Centre for Addiction and Mental Health. He is a Professor in the Departments of Family and Community Medicine, Psychiatry, and the Dalla Lana School of Public Health at the University of Toronto. He is also a Clinician Scientist in the Department of Family and Community Medicine. Dr. Selby is the Executive Director and creator of the TEACH project; a continuing education certificate program in Applied Counselling for Health with a focus on smoking cessation, through the University of Toronto. Dr. Selby’s research, as a Principal Investigator at the Ontario Tobacco Research Unit, includes smoking cessation especially in smokers with co-morbid conditions. As the Principal Investigator of the STOP Study, he investigates the effectiveness of NRT and counselling in different types of intervention settings. He is also the PI of CANADAPTT- a unique Canadian Smoking Cessation Guideline development and dissemination project. Dr. Selby also continues his clinical research with pregnant women who use substances and is the PI of a knowledge translation program (PREGNETS) to increase the adoption of evidence-based interventions with pregnant smokers. 

    He has received grant funding totaling over 80 million dollars from CIHR, NIH, and Ministry of Health and has published 130 peer reviewed publications. He has published 5 books (including 4 edited), is the author of 30 book chapters, and 32 research reports prepared for the government. He is the Co-Chair for the Ministry of Health Cessation Task force and the Chair of the Canadian Centre on Substance Abuse National Task Force on Treatment for Prescription Drug Misuse. Dr. Selby mentors Fellows in Addiction Medicine and Addiction Psychiatry, junior investigators and medical students. Dr. Selby a sought after speaker for various topics including addictive disorders, motivational interviewing, and health behavior change.

    Miriam S. Komaromy

    MD, FACP, DFASAM

    Dr. Komaromy is an Associate Professor of Medicine and Associate Director of the ECHO Institute (echo.unm.edu), which is a program based at the University of New Mexico Health Sciences Center that is aimed at expanding access to treatment for traditionally underserved populations. She is Director for the Integrated Addictions and Psychiatry teleECHO program, which engages and supports primary care teams in treating addiction and behavioral health disorders. Through this program she has trained more than 500 physicians to provide buprenorphine treatment for opioid use disorder. She is board certified in Addiction Medicine through the American Society of Addiction Medicine. She serves on several national committees focused on addiction medicine.. She practices addiction medicine in a primary care outpatient clinic setting, and is a newly elected Board Member for the American Society of Addiction Medicine (ASAM). She has served as medical director for the NM State Addiction Treatment Hospital. She lectures nationally on clinical and health policy issues related to integration of addiction treatment into the primary care setting, and on the use of the ECHO model to train primary care providers to treat common, complex diseases such as behavioral health and substance use disorders. 

  • Lifelong Learning: Review of Articles for Addiction Medicine MOC Part 2 (1.5 CME)

    Product not yet rated Contains 3 Component(s), Includes Credits

    This workshop will help meet MOC Part 2 requirements for attendees who are certified in Addiction Medicine by ABAM.

    Introduction: Maintenance of Certification (MOC) is a fundamental part of Addiction Medicine certification, and it can be important for patient care as well as professional development. MOC Part 2 (also known as Lifelong Learning and Self-Assessment) involves reading medical literature and answering questions based on articles, which is not always easy, especially for new or busy addiction medicine certified physicians. This workshop will help meet MOC Part 2 requirements for attendees who are certified in Addiction Medicine. Attendees who are not certified in addiction medicine can still learn about recent research from across the spectrum of the field of Addiction Medicine. This information will be discussed in terms of clinical relevance to patient care. Session description: Recent articles in addiction medicine selected for MOC Part 2 will be reviewed and critiqued to demonstrate the process and educate participants on the latest research findings in addiction medicine, including how this impacts patient care. Attendees will have a demonstration of the Addiction Medicine MOC web portal and have an opportunity to log on to review and participate in MOC Self-Assessment Modules (SAMs) in real time during this workshop (laptop or tablet with wifi connection required for this -- attendees will be informed to bring to the workshop if desired). Several articles from the SAMs will be described and discussed by experienced researcher-educators in Addiction Medicine from around the United States in an unbiased fashion, with attention paid to both strengths and limitations of each article. Each discussion will provide essential information to allow Addiction Medicine certified physicians to answer the SAM questions for each article if they desire, and receive credit through the web portal for participation in MOC Part 2, either during or after the workshop. Conclusions: Participants will gain an appreciation of the scope of recent research in Addiction Medicine and how it may impact patient care. In addition, participants will learn about new research that may potentially affect their practice. Addiction Medicine certified physicians who attend and are participating in MOC will be able to answer Part 2 Self-Assessment Module questions for MOC credit during this workshop.

    Michael Fingerhood

    MD, FACP

    Dr. Michael Fingerhood is an Associate Professor of Medicine at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance abuse treatment with primary medical care, including care for HIV and hepatitis C.

    Alexander Y. Walley

    MD, MSc, FASAM

    Alexander Y. Walley, M.D., M.Sc., is an Associate Professor of Medicine at Boston University School of Medicine, a general internist and addiction medicine specialist at Boston Medical Center. He is the director of the Addiction Medicine Fellowship program and founded the Inpatient Addiction Consult Service at Boston Medical Center. He does clinical and research-related work on the medical complications of substance use, specifically HIV and overdose. He provides primary care and office-based buprenorphine treatment for HIV patients and methadone maintenance treatment. He is the medical director for the Massachusetts Department of Public Health’s Opioid Overdose Prevention Pilot Program. 

    Lia Bennett

    MPH

    Lia Bennett is an independent consultant serving as the Director of Maintenance of Certification for the American Board of Addiction. She was a quality improvement program coordinator for the American College of Physicians and brings to ABAM, over 10 years of experience developing and managing MOC compliant programs. She has worked in the field of internal medicine conducting continuing medical education research in the areas of adult immunization, cardiovascular risk and diabetes. Ms. Bennett received her Masters of Public Health with a graduate certificate in Integrative Health. She strives to provide superior guidance to ABAM Diplomates.

  • The Nuts and Bolts of the Inpatient Substance Use Disorders Consultation (1.5 CME)

    Contains 3 Component(s), Includes Credits

    ​Substance use disorders are common, with a 12-month prevalence in the general population of 14% for alcohol and 4% for drug use disorders, respectively. Rates among hospitalized patients are notably higher with estimates of current substance use disorders among inpatients of up to 30%. Prior studies have suggested that hospitalization may be a "reachable moment" and is an ideal time to intervene with patients who have substance use disorders. This presentation will describe the procedures of an inpatient addiction consultation service.

    Substance use disorders are common, with a 12-month prevalence in the general population of 14% for alcohol and 4% for drug use disorders, respectively. Rates among hospitalized patients are notably higher with estimates of current substance use disorders among inpatients of up to 30%. Prior studies have suggested that hospitalization may be a "reachable moment" and is an ideal time to intervene with patients who have substance use disorders. The creation of specialized hospital-based services is one approach to the identification of and intervention with hospitalized patients with substance use disorders. However, whether or not your hospital has a specialized addiction consultation service, providers need to know how to prepare for and conduct an effective clinical consult for substance use. This workshop uses didactic instruction and small group case-based learning to teach learners the nuts and bolts of an effective consultation for substance misuse and use disorders. As opposed to teaching motivational interviewing skills, we will focus on the practical steps to consider and complete before, during and after the face-to face intervention. The session will begin with an introduction and a brief didactic overview which will focus on the three phases of the substance use disorder consult: pre-interview, face-to-face interview and post-interview. The emphasis of the overview will be on objectives for each phase of the clinical consultation, identification of and collaboration with local hospital-based and community treatment programs, special populations (e.g. Dual Diagnosis, LGBTQ, Sex Offenders, Medically Complex), and staffing of a multidisciplinary substance use disorder consultation team. The group will then break into three smaller groups for facilitated discussion based on several clinical scenarios. The clinical scenarios will cover various topics including: approach to patients in the precontemplation stage of change, requests for discontinuation of medication assisted treatment, and special populations. In each small group, a presenter will facilitate the dialogue ensuring discussion of take home points for each scenario. At the end of the session, the large group will reconvene. One participant from each small group will report on the content of their discussion providing an opportunity for cross-learning amongst workshop participants. Presenters will provide a brief summary emphasizing the key concepts for the workshop and answer any outstanding questions on the effective inpatient consultation for substance use. Participants will also be provided with references and resource material to which they can refer once they have returned to their respective practice settings.

    Anika Alvanzo

    MD, MS, FASAM, FACP

    Anika Alvanzo, MD, MS is an Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine where she is also the Medical Director of the Johns Hopkins Hospital Substance Use Disorders Consultation Service (SUDS). Dr. Alvanzo is a graduate of the George Washington University School of Medicine and Health Sciences and holds a master's degree in biostatistics from Virginia Commonwealth University. She is board certified in both Internal Medicine and Addiction Medicine. As the Director of the SUDS, Dr. Alvanzo oversees a multidisciplinary consultation service that performs brief behavioral interventions and counseling for hospitalized patients, facilitates linkage to hospital and community-based alcohol and drug treatment programs, provides guidance on the clinical management of substance withdrawal syndromes, and educates patients, families, healthcare professionals and the community to prevent, identify, and treat persons living with addiction. Dr. Alvanzo is also the Director of the Substance Use Disorders Rotation for the Johns Hopkins Medicine-Pediatrics Urban Health and Urban Health Primary Care Residency track programs. Her research interests include gender and race/ethnicity differences in the risk for substance use disorders, integration of technology for screening, brief intervention and referral to treatment in diverse settings and the association between psychological trauma, traumatic stress, and substance use. In particular, she is interested in the mechanisms by which histories of physical and/or sexual violence confer increased risk for substance use disorders and in the development of interventions for co-occurring traumatic stress and substance misuse in women.

    Patricia Burgee

    MSN, MBA, CARN

    Patti Burgee, MSN, MBA, CARN works for the Department of Medicine at Johns Hopkins Hospital in Baltimore, MD.  She is a graduate of the Towson University School of Nursing and holds masters’ degree in Healthcare Administration and Business from the Johns Hopkins School of Nursing and Carey Business School. She has worked in various clinical and administrative roles at Johns Hopkins Hospital for 30 years. In her position as the Nurse Coordinator for the Substance Use Disorders Consultation Service since September 2010, Patti conducts brief, bedside interventions, counseling and referral to treatment for medically ill patients with substance use disorders. 

    Diane Moses

    MEd, MSW, LCAD-C

    Diane Moses, MEd, MSW, LCAD-C is a Senior Addiction Therapist at Johns Hopkins Hospital.